Your genomic expert for biologics testing

Your benefit: A step ahead with our know how and customized services

  • Accelerate your drug development by a ensuring fast, comprehensive viral safety testing package
  • Decrease your risk of a false positive by applying the PathoQuest viral safety NGS transcriptome approach
  • De-risk your drug development pipeline using a broad-range, powerful safety test

Metagenomics NGS Services offered by PathoQuest are fast, cost-effective and fully integrated. High Throughput Sequencing services are dedicated to genetic characterization and viral safety testing allowing you to do one test instead of multiple assays.

Genomic Testing for Vaccines

  • Our non-targeted approach enables the detection of a broad range of viruses 
  • No need for specific amplification (cell culture, in vivo…)
  • Capacity to detect new viral variants
  • Upfront sample preparation may be adapted to many matrix including cell banks, virus stocks, raw materials and product intermediates
  • Avoid development of specific neutralizing antibody (no antiserum from animal origin)
  • Turnaround time < 3 days (Emergency test)
  • Our proprietary sample preparation process enables the detection of adventitious virus in highly concentrated vaccinal viral seed stocks and bulk harvest
  • Enables detection of RNA and DNA viruses (2 tests)

 

Genomic Testing for Biologics

  • Our non-targeted approach enables the detection of a broad range of viruses 
  • Using a transcritomic (RNASeq) NGS approach at the preMCB level ensures the highest safety level and de-risks the drug development process
  • Our trancriptomic NGS approach detects only replicative viruses and reduces the risk of false positives (dead viral sequences, wrong taxonomic assignation, etc.)
  • The high precision (accuracy) of Illumina sequencing enables precise genome analysis to document purity and the clonality of cell lines

 

Genomic Testing for Gene & Cell Therapy

  • Our non-targeted approach enables the detection of a broad range of viruses 
  • Using a transcritomic (RNASeq) NGS approach at the preMCB level ensures the highest safety level and de-risks the drug development process
  • Our trancriptomic NGS approach detects only replicative viruses and reduces the risk of false positives (dead viral sequences, wrong taxonomic assignation, etc.)
  • The high precision (accuracy) of Illumina sequencing enable precise genome analysis to document the vector and insertion sites sequence in the modified cells